Novel therapeutic target for diabetic kidney disease through ...
Seven weeks of celastrol (1.5 mg/kg/day) treatment significantly ameliorated DKD. Celastrol improves kidney functions. Moreover, celastrol treatment demonstrated potent antioxidant effect.
Novel therapeutic target for diabetic kidney disease through ...
2024年12月19日 · Seven weeks of celastrol (1.5 mg/kg/day) treatment significantly ameliorated DKD. Celastrol improves kidney functions. Moreover, celastrol treatment demonstrated potent antioxidant effect. The mechanism of apoptosis resulting from the administration of celastrol included the modulation of Bcl-2 and caspase-3 expression in the kidney.
Molecular Therapeutics for Diabetic Kidney Disease: An Update
2024年9月19日 · Celastrol, an inhibitor of NF-κB, can improve insulin resistance and play an anti-inflammatory role, making it a new useful method for treating DKD . In addition, the NF-κB inhibitor, BAY 11-7082 and a small molecule analog of resveratrol, have been reported to reduce renal inflammation in mouse models of DKD by inhibiting the activation of ...
Study of molecular mechanisms underlying the medicinal plant ...
Celastrol, a quinone methide triterpene, extracted from Tripterygium wilfordii has been shown to possess various pharmacological properties, including anti-inflammatory, anti-autoimmune, anti-cancer, and neuroprotective activities (Wagh et al., 2021; Lim et al., 2021; Gu et al., 2018).
Macrophage inflammatory protein-1β as a novel ... - ScienceDirect
2023年5月1日 · Pre-clinical studies have shown that different interventions targeting inflammation modulation can successfully attenuate DKD severity. Celastrol has been shown to protect against podocyte injury and insulin resistance induced by high glucose by restoring the heme oxygenase-1-mediated autophagy pathway [24].
Piao LUO | Medical Professional | Southern Medical University ...
Celastrol, a natural bioactive triterpenoid extracted from Tripterygium wilfordii, shows effective anti-fibrotic and anti-inflammatory activities in multiple hepatic diseases.
Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and ...
2013年4月26日 · We investigated the effects of the NF-κB inhibitor celastrol in db/db mice. The treatment with celastrol for 2 months significantly lowered fasting plasma glucose (FPG), HbA1C and homeostasis model assessment index (HOMA-IR) levels. Celastrol also exhibited significant decreases in body weight, kidney/body weight and adiposity.
Celastrol antagonizes high glucose-evoked podocyte injury, …
2018年12月1日 · In this review, we briefly summarize underlying mechanisms of autophagy dysregulation in DKD, including AMP-activated protein kinase (AMPK), the mechanistic target of rapamycin (mTOR), and the ...
Celastrol in metabolic diseases: Progress and application prospects
2021年5月1日 · Celastrol-regulated cellular signaling pathways leading to insulin resistance reversal in treating diabetes. Celastrol reversed insulin resistance by disrupting PA and MD2 interaction, thus preventing TLR4-dependent NF-κB activation. Celastrol increased PA-decreased miR-223 level and GLUT4 protein expression in HepG2 cells.
Targeting endothelin signaling in podocyte injury and diabetic ...
2024年9月20日 · This article aims to elucidate the role of endothelin in podocyte injury in DN-DKD, highlighting its potential as a therapeutic target to arrest or reverse disease progression. Furthermore, this review elaborates on the latest evidence of combining these drugs with the standard treatments of DN-DKD.